Sangamo Therapeutics Company Profile (NASDAQ:SGMO)

About Sangamo Therapeutics (NASDAQ:SGMO)

Sangamo Therapeutics logoSangamo Therapeutics, Inc., formerly Sangamo BioSciences, Inc., is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients' lives using the Company's platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company has clinical and preclinical programs in development and partnered certain programs with biopharmaceutical companies to expedite clinical and commercial development. The focus for its Company is the development of human therapeutics. The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. The Company has initiated a Phase I/II clinical trial evaluating its zinc finger nuclease (ZFN) in vivo genome editing approach for the treatment of hemophilia B. In the development of its ZFP technology platform, it is focusing its resources on product development for therapeutic use in humans and on its non-therapeutic applications.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:SGMO
  • CUSIP: 80067710
  • Web:
  • Market Cap: $1.21236 billion
  • Outstanding Shares: 83,610,000
Average Prices:
  • 50 Day Moving Avg: $14.51
  • 200 Day Moving Avg: $9.39
  • 52 Week Range: $2.65 - $17.06
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -17.69
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $23.42 million
  • Price / Sales: 50.52
  • Book Value: $2.32 per share
  • Price / Book: 6.10
  • EBITDA: ($57,470,000.00)
  • Net Margins: -246.39%
  • Return on Equity: -38.49%
  • Return on Assets: -30.67%
  • Debt-to-Equity Ratio: 0.02%
  • Current Ratio: 6.14%
  • Quick Ratio: 6.14%
  • Average Volume: 1.62 million shs.
  • Beta: 3.14
  • Short Ratio: 8.11

Frequently Asked Questions for Sangamo Therapeutics (NASDAQ:SGMO)

What is Sangamo Therapeutics' stock symbol?

Sangamo Therapeutics trades on the NASDAQ under the ticker symbol "SGMO."

How were Sangamo Therapeutics' earnings last quarter?

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) posted its quarterly earnings data on Wednesday, August, 9th. The company reported ($0.17) EPS for the quarter, topping analysts' consensus estimates of ($0.23) by $0.06. The business had revenue of $8.30 million for the quarter, compared to analyst estimates of $5.82 million. Sangamo Therapeutics had a negative return on equity of 38.49% and a negative net margin of 246.39%. The firm's revenue for the quarter was up 124.3% on a year-over-year basis. During the same period in the previous year, the company posted ($0.38) earnings per share. View Sangamo Therapeutics' Earnings History.

When will Sangamo Therapeutics make its next earnings announcement?

Sangamo Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, October, 24th 2017. View Earnings Estimates for Sangamo Therapeutics.

Where is Sangamo Therapeutics' stock going? Where will Sangamo Therapeutics' stock price be in 2017?

5 equities research analysts have issued 12 month price objectives for Sangamo Therapeutics' shares. Their forecasts range from $4.00 to $30.00. On average, they expect Sangamo Therapeutics' share price to reach $15.00 in the next year. View Analyst Ratings for Sangamo Therapeutics.

What are analysts saying about Sangamo Therapeutics stock?

Here are some recent quotes from research analysts about Sangamo Therapeutics stock:

  • 1. According to Zacks Investment Research, "Sangamo Therapeutics, Inc. is a biotechnology company. It focuses on research and development of genomic therapies as well as develops medicines for patient with genetic diseases. The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. Sangamo Therapeutics Inc., formerly known as Sangamo BioSciences Inc., is based in Richmond, United States. " (8/18/2017)
  • 2. Cowen and Company analysts commented, "We hosted a group lunch meeting with SGMO management this week." (3/22/2017)
  • 3. Piper Jaffray Companies analysts commented, "Today Sangamo reported 4Q16 financial results, ending the quarter with ~$143M in cash. With updated 2017 guidance on operating expenses incorporated into our model, we expect this cash runway can fund the company through 1H18. This period should include the first safety and biomarker data from early cohorts of patients treated in its open, or soon-to-be opened, clinical trials for Hem A, Hem B, MPS I, and MPS II. Although we expect these early results in late'17/early '18 to focus primarily on safety and pharmacodynamic signals of activity and thus not yet be definitive for informing pivotal programs, we nonetheless believe this progress to be critical for evaluating turn-around efforts and establishing a new era of clinical achievement for Sangamo. That said, in advance of enrollment updates and increased visibility on clinical progress for Sangamo's broadening but early pipeline, we remain on the sidelines with a Neutral rating." (2/28/2017)

Who are some of Sangamo Therapeutics' key competitors?

Who are Sangamo Therapeutics' key executives?

Sangamo Therapeutics' management team includes the folowing people:

  • Alexander D. Macrae Ph.D., President, Chief Executive Officer, Director
  • Kathy Y. Yi, Chief Financial Officer, Senior Vice President
  • Edward R. Conner M.D., Senior Vice President and Chief Medical Officer
  • Curt Herberts III, Senior Vice President and Chief Business Officer
  • Dale G. Ando M.D., Vice President - Therapeutic Development, Chief Medical Officer
  • Roger Jeffs Ph.D., Director
  • Joseph S. Zakrzewski, Director
  • Robert F. Carey, Independent Director
  • Stephen G. Dilly M.D. Ph.D., Independent Director
  • Steven J. Mento Ph.D., Independent Director

How do I buy Sangamo Therapeutics stock?

Shares of Sangamo Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sangamo Therapeutics' stock price today?

One share of Sangamo Therapeutics stock can currently be purchased for approximately $14.15.

MarketBeat Community Rating for Sangamo Therapeutics (NASDAQ SGMO)
Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  193 (Vote Outperform)
Underperform Votes:  147 (Vote Underperform)
Total Votes:  340
MarketBeat's community ratings are surveys of what our community members think about Sangamo Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Sangamo Therapeutics (NASDAQ:SGMO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.60)
Consensus Price Target: $15.00 (6.01% upside)
Consensus Price Target History for Sangamo Therapeutics (NASDAQ:SGMO)
Price Target History for Sangamo Therapeutics (NASDAQ:SGMO)
Analysts' Ratings History for Sangamo Therapeutics (NASDAQ:SGMO)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/13/2017Jefferies Group LLCReiterated RatingBuy$18.00N/AView Rating Details
9/5/2017Wells Fargo & CompanyReiterated RatingOutperform$20.00 -> $30.00LowView Rating Details
8/10/2017Piper Jaffray CompaniesSet Price TargetHold$8.00HighView Rating Details
5/16/2017WedbushReiterated RatingNeutral$6.00 -> $4.00MediumView Rating Details
3/22/2017Cowen and CompanyReiterated RatingBuyHighView Rating Details
8/4/2016Janney Montgomery ScottDowngradeBuy -> Neutral$15.00 -> $8.00N/AView Rating Details
2/10/2016J P Morgan Chase & CoReiterated RatingOverweight$16.00N/AView Rating Details
(Data available from 10/19/2015 forward)


Earnings History for Sangamo Therapeutics (NASDAQ:SGMO)
Earnings by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)
Earnings History by Quarter for Sangamo Therapeutics (NASDAQ SGMO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/24/2017($0.19)N/AView Earnings Details
8/9/2017Q2 2017($0.23)($0.17)$5.82 million$8.30 millionViewListenView Earnings Details
5/10/2017Q1 2017($0.26)($0.23)$4.14 million$3.40 millionViewN/AView Earnings Details
2/28/2017Q416($0.26)($0.14)$3.91 million$8.90 millionViewListenView Earnings Details
10/26/2016Q316($0.25)($0.27)$4.24 million$2.82 millionViewListenView Earnings Details
8/3/2016Q216($0.24)($0.38)$5.38 million$3.70 millionViewN/AView Earnings Details
5/2/2016Q116($0.24)($0.23)$5.49 million$3.94 millionViewN/AView Earnings Details
2/9/2016Q415($0.21)($0.20)$9.86 million$9.10 millionViewN/AView Earnings Details
10/28/2015Q315($0.25)($0.13)$13.09 million$8.57 millionViewListenView Earnings Details
8/5/2015Q215($0.13)($0.17)$14.72 million$8.36 millionViewListenView Earnings Details
4/22/2015Q115($0.13)($0.08)$12.50 million$13.50 millionViewListenView Earnings Details
2/10/2015Q414($0.09)($0.06)$14.50 million$15.00 millionViewN/AView Earnings Details
10/22/2014Q314($0.04)($0.11)$8.27 million$12.40 millionViewListenView Earnings Details
7/23/2014Q214($0.14)($0.10)$7.84 million$10.38 millionViewListenView Earnings Details
5/6/2014Q114($0.13)($0.12)$6.59 million$8.10 millionViewListenView Earnings Details
2/11/2014Q413($0.10)($0.13)$8.90 million$6.90 millionViewListenView Earnings Details
10/23/2013Q313($0.11)($0.11)$5.52 million$5.70 millionViewN/AView Earnings Details
7/24/2013Q2 2013($0.12)($0.10)$4.77 million$6.90 millionViewN/AView Earnings Details
5/8/2013Q1 2013($0.17)($0.13)$3.79 million$4.60 millionViewN/AView Earnings Details
2/6/2013Q4 2012($0.12)($0.07)$5.95 million$8.93 millionViewN/AView Earnings Details
10/24/2012Q312($0.14)($0.11)$3.80 million$4.90 millionViewN/AView Earnings Details
7/25/2012($0.15)($0.11)ViewN/AView Earnings Details
5/2/2012($0.16)($0.14)ViewN/AView Earnings Details
10/25/2011($0.16)($0.18)ViewN/AView Earnings Details
7/27/2011($0.16)($0.20)ViewN/AView Earnings Details
4/26/2011($0.17)($0.21)ViewN/AView Earnings Details
2/2/2011($0.19)($0.18)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Sangamo Therapeutics (NASDAQ:SGMO)
2017 EPS Consensus Estimate: ($0.87)
2018 EPS Consensus Estimate: ($0.98)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.25)($0.23)($0.24)
Q2 20172($0.23)($0.12)($0.18)
Q3 20172($0.22)($0.21)($0.22)
Q4 20172($0.25)($0.23)($0.24)
Q1 20181($0.25)($0.25)($0.25)
Q2 20181($0.25)($0.25)($0.25)
Q3 20181($0.24)($0.24)($0.24)
Q4 20181($0.24)($0.24)($0.24)
(Data provided by Zacks Investment Research)


Dividend History for Sangamo Therapeutics (NASDAQ:SGMO)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Sangamo Therapeutics (NASDAQ:SGMO)
Insider Ownership Percentage: 5.50%
Institutional Ownership Percentage: 63.43%
Insider Trades by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)
Institutional Ownership by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)
Insider Trades by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/2/2017Curt A Herberts IIIVPSell15,000$15.25$228,750.00View SEC Filing  
9/20/2017William R RingoDirectorSell31,000$14.37$445,470.00View SEC Filing  
9/1/2017Curt A Herberts IIIVPSell15,000$15.00$225,000.00View SEC Filing  
8/14/2017Curt A Herberts IIIVPSell11,474$10.44$119,788.56View SEC Filing  
7/14/2017Curt A Herberts IIIVPSell15,000$10.00$150,000.00View SEC Filing  
6/1/2017Curt A. Herberts IIIVPSell2,000$6.80$13,600.00View SEC Filing  
5/12/2017Curt A. Herberts IIIVPSell2,639$8.02$21,164.78View SEC Filing  
8/1/2015Ra Capital Management, LlcMajor ShareholderSell27,770$12.82$356,011.40View SEC Filing  
7/30/2015Ra Capital Management, LlcMajor ShareholderSell109,590$12.42$1,361,107.80View SEC Filing  
7/29/2015Ra Capital Management, LlcMajor ShareholderSell1,407$12.41$17,460.87View SEC Filing  
7/28/2015Ra Capital Management, LlcMajor ShareholderSell60,081$12.11$727,580.91View SEC Filing  
7/25/2015Ra Capital Management, LlcMajor ShareholderSell47,429$12.31$583,850.99View SEC Filing  
7/24/2015Ra Capital Management, LlcMajor ShareholderSell124,050$12.28$1,523,334.00View SEC Filing  
7/17/2015Ra Capital Management, LlcMajor ShareholderBuy37,215$12.26$456,255.90View SEC Filing  
7/15/2015Edward O Lanphier IICEOSell25,000$10.43$260,750.00View SEC Filing  
7/13/2015Henry Ward WolffCFOSell12,000$10.00$120,000.00View SEC Filing  
7/1/2015Ra Capital Management, LlcMajor ShareholderSell82,700$16.01$1,324,027.00View SEC Filing  
6/16/2015Ra Capital Management, LlcMajor ShareholderSell250,500$16.55$4,145,775.00View SEC Filing  
6/9/2015Ra Capital Management, LlcMajor ShareholderSell83,500$15.50$1,294,250.00View SEC Filing  
6/6/2015Ra Capital Management, LlcMajor ShareholderSell135,101$14.29$1,930,593.29View SEC Filing  
6/5/2015Dale G AndoCMOSell15,000$12.29$184,350.00View SEC Filing  
6/5/2015Ra Capital Management, LlcMajor ShareholderSell115,102$14.13$1,626,391.26View SEC Filing  
6/4/2015Ra Capital Management, LlcMajor ShareholderSell70,640$13.10$925,384.00View SEC Filing  
6/3/2015Ra Capital Management, LlcMajor ShareholderSell76,833$12.86$988,072.38View SEC Filing  
6/3/2015William R RingoDirectorSell2,200$12.44$27,368.00View SEC Filing  
6/1/2015Philip D GregorySVPSell15,000$12.39$185,850.00View SEC Filing  
5/30/2015Ra Capital Management, LlcMajor ShareholderSell65,884$13.40$882,845.60View SEC Filing  
5/29/2015Ra Capital Management, LlcMajor ShareholderSell155,675$13.53$2,106,282.75View SEC Filing  
5/28/2015Ra Capital Management, LlcMajor ShareholderSell148,689$13.43$1,996,893.27View SEC Filing  
5/27/2015Ra Capital Management, LlcMajor ShareholderSell263,437$13.55$3,569,571.35View SEC Filing  
5/23/2015Ra Capital Management, LlcMajor ShareholderSell51,597$13.27$684,692.19View SEC Filing  
5/22/2015Ra Capital Management, LlcMajor ShareholderSell56,396$13.56$764,729.76View SEC Filing  
5/13/2015Ra Capital Management, LlcMajor ShareholderSell56,060$13.12$735,507.20View SEC Filing  
5/12/2015Ra Capital Management, LlcMajor ShareholderSell29,659$13.03$386,456.77View SEC Filing  
5/8/2015Ra Capital Management, LlcMajor ShareholderSell83,300$12.40$1,032,920.00View SEC Filing  
5/7/2015Ra Capital Management, LlcMajor ShareholderBuy35,736$12.09$432,048.24View SEC Filing  
5/5/2015Dale G AndoCMOSell15,000$12.29$184,350.00View SEC Filing  
5/4/2015William R RingoDirectorSell3,000$12.98$38,940.00View SEC Filing  
4/30/2015Ra Capital Management, LlcMajor ShareholderBuy124,500$13.45$1,674,525.00View SEC Filing  
4/28/2015Ra Capital Management, LlcMajor ShareholderBuy74,844$13.29$994,676.76View SEC Filing  
4/25/2015Ra Capital Management, LlcMajor ShareholderBuy166,000$13.63$2,262,580.00View SEC Filing  
4/22/2015Ra Capital Management, LlcMajor ShareholderSell352,750$14.86$5,241,865.00View SEC Filing  
4/17/2015Ra Capital Management, LlcMajor ShareholderBuy41,500$14.02$581,830.00View SEC Filing  
4/16/2015Ra Capital Management, LlcMajor ShareholderSell21,829$14.09$307,570.61View SEC Filing  
4/15/2015Edward O Lanphier IICEOSell25,000$15.33$383,250.00View SEC Filing  
4/15/2015Ra Capital Management, LlcMajor ShareholderBuy21,829$13.16$287,269.64View SEC Filing  
4/14/2015Ra Capital Management, LlcMajor ShareholderSell3,055$14.78$45,152.90View SEC Filing  
4/11/2015Ra Capital Management, LlcMajor ShareholderBuy116,992$14.48$1,694,044.16View SEC Filing  
4/10/2015Henry Ward WolffCFOSell12,000$15.31$183,720.00View SEC Filing  
4/10/2015Ra Capital Management, LlcMajor ShareholderBuy83,000$14.91$1,237,530.00View SEC Filing  
4/9/2015Ra Capital Management, LlcMajor ShareholderSell69,856$16.27$1,136,557.12View SEC Filing  
4/8/2015Ra Capital Management, LlcMajor ShareholderBuy121,876$15.49$1,887,859.24View SEC Filing  
4/7/2015Ra Capital Management, LlcMajor ShareholderBuy33,667$15.42$519,145.14View SEC Filing  
4/6/2015Dale G AndoCMOSell15,000$14.94$224,100.00View SEC Filing  
4/6/2015William R RingoDirectorSell2,200$14.95$32,890.00View SEC Filing  
4/4/2015Ra Capital Management, LlcMajor ShareholderBuy179,031$15.38$2,753,496.78View SEC Filing  
4/3/2015Ra Capital Management, LlcMajor ShareholderBuy195,126$16.61$3,241,042.86View SEC Filing  
4/1/2015Philip D GregorySVPSell15,000$15.15$227,250.00View SEC Filing  
4/1/2015Ra Capital Management, LlcMajor ShareholderSell250,000$18.01$4,502,500.00View SEC Filing  
3/28/2015Ra Capital Management, LlcMajor ShareholderBuy84,000$17.10$1,436,400.00View SEC Filing  
3/27/2015Ra Capital Management, LlcMajor ShareholderBuy256,187$17.65$4,521,700.55View SEC Filing  
3/26/2015Ra Capital Management, LlcMajor ShareholderBuy210,013$18.14$3,809,635.82View SEC Filing  
3/25/2015Ra Capital Management, LlcMajor ShareholderBuy84,000$19.42$1,631,280.00View SEC Filing  
3/21/2015Ra Capital Management, LlcMajor ShareholderBuy101,808$21.22$2,160,365.76View SEC Filing  
3/19/2015Henry Ward WolffCFOSell10,000$18.00$180,000.00View SEC Filing  
3/19/2015Ra Capital Management, LlcMajor ShareholderSell17,808$24.28$432,378.24View SEC Filing  
3/18/2015Ra Capital Management, LlcMajor ShareholderSell84,000$23.74$1,994,160.00View SEC Filing  
3/17/2015Ra Capital Management, LlcMajor ShareholderBuy52,161$23.02$1,200,746.22View SEC Filing  
3/16/2015Edward O Lanphier IICEOSell25,000$17.29$432,250.00View SEC Filing  
3/13/2015Ra Capital Management, LlcMajor ShareholderBuy71,319$22.76$1,623,220.44View SEC Filing  
3/12/2015Ra Capital Management, LlcMajor ShareholderSell123,480$23.40$2,889,432.00View SEC Filing  
3/10/2015Ra Capital Management, LlcMajor ShareholderBuy12,522$22.30$279,240.60View SEC Filing  
3/7/2015Ra Capital Management, LlcMajor ShareholderBuy258,377$22.25$5,748,888.25View SEC Filing  
3/6/2015Ra Capital Management, LlcMajor ShareholderSell61,483$24.10$1,481,740.30View SEC Filing  
3/3/2015Ra Capital Management, LlcMajor ShareholderSell84,000$18.21$1,529,640.00View SEC Filing  
3/3/2015William R RingoDirectorSell2,200$17.21$37,862.00View SEC Filing  
3/2/2015Philip D GregorySVPSell15,000$17.26$258,900.00View SEC Filing  
2/28/2015Ra Capital Management, LlcMajor ShareholderBuy42,000$18.10$760,200.00View SEC Filing  
2/27/2015Ra Capital Management, LlcMajor ShareholderSell32,196$19.37$623,636.52View SEC Filing  
2/26/2015Ra Capital Management, LlcMajor ShareholderBuy74,194$19.57$1,451,976.58View SEC Filing  
2/20/2015Ra Capital Management, LlcMajor ShareholderSell35,319$18.40$649,869.60View SEC Filing  
2/19/2015Ra Capital Management, LlcMajor ShareholderSell6,720$18.51$124,387.20View SEC Filing  
2/18/2015Ra Capital Management, LlcMajor ShareholderSell11,172$18.11$202,324.92View SEC Filing  
2/14/2015Ra Capital Management, LlcMajor ShareholderSell15,380$18.61$286,221.80View SEC Filing  
2/13/2015Ra Capital Management, LlcMajor ShareholderSell15,409$18.46$284,450.14View SEC Filing  
2/12/2015Ra Capital Management, LlcMajor ShareholderBuy42,000$18.04$757,680.00View SEC Filing  
2/12/2015Saira RamasastryDirectorSell10,000$15.00$150,000.00View SEC Filing  
2/11/2015Ra Capital Management, LlcMajor ShareholderBuy42,000$19.65$825,300.00View SEC Filing  
2/7/2015Ra Capital Management, LlcMajor ShareholderSell34,688$18.52$642,421.76View SEC Filing  
2/6/2015Ra Capital Management, LlcMajor ShareholderSell7,312$18.42$134,687.04View SEC Filing  
2/5/2015Dale G AndoCMOSell15,000$12.93$193,950.00View SEC Filing  
2/5/2015Ra Capital Management, LlcMajor ShareholderBuy42,000$18.23$765,660.00View SEC Filing  
2/3/2015William R RingoDirectorSell2,200$12.70$27,940.00View SEC Filing  
2/2/2015Philip D GregorySVPSell15,000$12.86$192,900.00View SEC Filing  
1/16/2015Edward O Lanphier IICEOSell25,000$14.22$355,500.00View SEC Filing  
1/12/2015Henry Ward WolffCFOSell12,000$15.87$190,440.00View SEC Filing  
1/5/2015Dale G AndoCMOSell15,000$15.19$227,850.00View SEC Filing  
1/5/2015William R RingoDirectorSell2,200$15.20$33,440.00View SEC Filing  
12/15/2014Edward O Lanphier IICEOSell25,000$15.40$385,000.00View SEC Filing  
12/15/2014John William LarsonDirectorSell10,000$16.28$162,800.00View SEC Filing  
12/9/2014John William LarsonDirectorSell10,000$12.00$120,000.00View SEC Filing  
12/1/2014Philip D GregorySVPSell15,000$11.68$175,200.00View SEC Filing  
11/17/2014Edward O Lanphier IICEOSell25,000$11.23$280,750.00View SEC Filing  
11/12/2014John William LarsonDirectorSell10,000$12.00$120,000.00View SEC Filing  
11/3/2014Philip D GregorySVPSell15,000$11.91$178,650.00View SEC Filing  
10/28/2014John William LarsonDirectorSell10,000$12.02$120,200.00View SEC Filing  
10/10/2014Henry Ward WolffCFOSell2,000$10.10$20,200.00View SEC Filing  
10/6/2014Dale G AndoCMOSell15,000$10.72$160,800.00View SEC Filing  
10/1/2014Philip D GregorySVPSell15,000$10.80$162,000.00View SEC Filing  
9/15/2014Edward O Lanphier IICEOSell25,000$12.14$303,500.00View SEC Filing  
9/10/2014Henry Ward WolffCFOSell2,000$12.31$24,620.00View SEC Filing  
9/5/2014Dale G AndoCMOSell15,000$12.20$183,000.00View SEC Filing  
9/4/2014John William LarsonDirectorSell10,000$12.81$128,100.00View SEC Filing  
8/15/2014Edward O Lanphier IICEOSell25,000$13.95$348,750.00View SEC Filing  
8/11/2014Henry Ward WolffCFOSell10,000$14.17$141,700.00View SEC Filing  
8/5/2014Dale G AndoCMOSell15,000$12.99$194,850.00View SEC Filing  
8/4/2014John William LarsonDirectorSell10,000$12.56$125,600.00View SEC Filing  
8/1/2014Philip D GregorySVPSell15,000$12.54$188,100.00View SEC Filing  
7/18/2014Edward O Lanphier IICEOSell25,000$12.16$304,000.00View SEC Filing  
7/10/2014Henry Ward WolffCFOSell15,000$13.26$198,900.00View SEC Filing  
7/1/2014Philip D GregorySVPSell15,000$15.66$234,900.00View SEC Filing  
6/23/2014Saira RamasastryDirectorSell5,550$15.53$86,191.50View SEC Filing  
6/16/2014Edward O Lanphier IICEOSell25,000$16.41$410,250.00View SEC Filing  
6/10/2014Henry Ward WolffCFOSell15,000$15.62$234,300.00View SEC Filing  
6/2/2014Philip D GregorySVPSell15,000$12.85$192,750.00View SEC Filing  
5/15/2014Edward Lanphier IICEOSell25,000$13.14$328,500.00View SEC Filing  
5/1/2014Philip GregorySVPSell15,000$13.68$205,200.00View SEC Filing  
4/28/2014Dale AndoCMOSell15,000$13.64$204,600.00View SEC Filing  
4/28/2014John William LarsonDirectorSell10,000$13.48$134,800.00View SEC Filing  
4/15/2014Edward Lanphier IICEOSell25,000$14.20$355,000.00View SEC Filing  
4/10/2014Henry Ward WolffCFOSell15,000$15.72$235,800.00View SEC Filing  
3/26/2014Dale AndoCMOSell15,000$18.65$279,750.00View SEC Filing  
3/21/2014Philip GregoryInsiderSell15,000$22.38$335,700.00View SEC Filing  
3/17/2014Edward Lanphier IICEOSell50,000$23.22$1,161,000.00View SEC Filing  
3/17/2014Saira RamasastryDirectorSell10,000$23.26$232,600.00View SEC Filing  
3/14/2014Steven MentoDirectorSell6,103$22.77$138,965.31View SEC Filing  
2/18/2014Edward Lanphier IICEOSell50,000$18.09$904,500.00View SEC Filing  
1/27/2014Dale AndoCMOSell15,000$18.58$278,700.00View SEC Filing  
1/10/2014Henry Ward WolffCFOSell10,000$18.69$186,900.00View SEC Filing  
1/2/2014Philip GregoryVPSell15,000$13.56$203,400.00View SEC Filing  
12/26/2013Dale AndoCMOSell15,000$14.37$215,550.00View SEC Filing  
11/15/2013Edward Lanphier IICEOSell25,000$10.11$252,750.00View SEC Filing  
11/5/2013Philip D GregoryVPSell15,000$9.60$144,000.00View SEC Filing  
10/28/2013Dale G AndoCMOSell15,000$10.39$155,850.00View SEC Filing  
10/21/2013Paul B ClevelandDirectorSell10,000$10.93$109,300.00View SEC Filing  
10/15/2013Edward O Lanphier IICEOSell25,000$11.32$283,000.00View SEC Filing  
10/10/2013Henry Ward WolffCFOSell10,000$11.28$112,800.00View SEC Filing  
10/1/2013Philip D GregoryVPSell15,000$10.54$158,100.00View SEC Filing  
9/16/2013Edward Lanphier IICEOSell25,000$11.29$282,250.00View SEC Filing  
9/10/2013Henry Ward WolffCFOSell10,000$10.86$108,600.00View SEC Filing  
9/3/2013Paul ClevelandDirectorSell7,278$10.30$74,963.40View SEC Filing  
9/3/2013Philip GregoryVPSell15,000$10.33$154,950.00View SEC Filing  
8/26/2013Dale AndoCMOSell15,000$10.04$150,600.00View SEC Filing  
8/15/2013Edward Lanphier IICEOSell25,000$10.12$253,000.00View SEC Filing  
8/13/2013Henry Ward WolffCFOSell10,000$10.00$100,000.00View SEC Filing  
8/1/2013Philip GregoryVPSell15,000$9.89$148,350.00View SEC Filing  
7/29/2013Philip D GregoryVPSell15,000$10.04$150,600.00View SEC Filing  
7/26/2013Dale G AndoCMOSell15,000$10.09$151,350.00View SEC Filing  
7/17/2013Edward O Lanphier IICEOSell25,000$10.00$250,000.00View SEC Filing  
7/17/2013Henry Ward WolffCFOSell10,000$10.00$100,000.00View SEC Filing  
7/15/2013Paul B ClevelandDirectorSell8,000$9.59$76,720.00View SEC Filing  
6/3/2013Philip D GregoryVPSell3,000$7.88$23,640.00View SEC Filing  
5/28/2013Dale G AndoCMOSell15,000$8.32$124,800.00View SEC Filing  
4/10/2013Henry Ward WolffCFOSell10,000$10.00$100,000.00View SEC Filing  
12/26/2012Dale G AndoCMOSell17,000$5.92$100,640.00View SEC Filing  
12/3/2012John William LarsonDirectorSell15,000$5.64$84,600.00View SEC Filing  
9/5/2012Dale G AndoCMOSell15,000$5.60$84,000.00View SEC Filing  
9/4/2012John William LarsonDirectorSell15,000$5.30$79,500.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Sangamo Therapeutics (NASDAQ:SGMO)
Latest Headlines for Sangamo Therapeutics (NASDAQ:SGMO)
DateHeadline logoSangamo Therapeutics Announces Presentations At 2017 Annual Congress Of The European Society Of Gene And Cell Therapy - October 18 at 8:28 AM logoETFs with exposure to Sangamo Therapeutics, Inc. : October 16, 2017 - October 17 at 7:14 AM logoSangamo Therapeutics, Inc. (SGMO) to Release Earnings on Tuesday - October 17 at 6:26 AM logoSangamo Therapeutics, Inc. (SGMO) Earns Buy Rating from Jefferies Group LLC - October 14 at 7:40 AM logoNeurocrine Biosciences (NBIX) & Sangamo Therapeutics (SGMO) Head-To-Head Review - October 13 at 2:20 PM logoSangamo Therapeutics, Inc. (SGMO) Expected to Post Quarterly Sales of $9.42 Million - October 13 at 10:44 AM logoSangamo Therapeutics, Inc. (SGMO) Expected to Announce Earnings of -$0.20 Per Share - October 11 at 6:18 PM logoSangamo Therapeutics, Inc. :SGMO-US: Earnings Analysis: Q2, 2017 By the Numbers : October 4, 2017 - October 6 at 9:54 AM logoETFs with exposure to Sangamo Therapeutics, Inc. : October 5, 2017 - October 6 at 9:53 AM logoInsider Selling: Sangamo Therapeutics, Inc. (SGMO) VP Sells 15,000 Shares of Stock - October 4 at 8:02 PM logoCan Sangamo Therapeutics Inc (SGMO) Improve Your Portfolio Returns? - October 3 at 12:19 PM logoSangamo And Bioverativ Announce FDA Acceptance Of IND Application For ST-400 -- A Gene-Edited Cell Therapy Candidate -- To Treat Beta-Thalassemia - October 2 at 9:35 AM logoSangamo Therapeutics Announces Participation At Upcoming Investor And Industry Conferences - September 29 at 5:10 AM logoSangamo Therapeutics (SGMO) Presents At Cantor Fitzgerald Global Healthcare Conference - Slideshow - September 29 at 5:10 AM logoHead-To-Head Review: Radius Health (RDUS) & Sangamo Therapeutics (SGMO) - September 27 at 2:12 PM logoSangamo Therapeutics, Inc. (SGMO) Receives Consensus Rating of "Hold" from Brokerages - September 27 at 12:54 PM logo$9.42 Million in Sales Expected for Sangamo Therapeutics, Inc. (SGMO) This Quarter - September 25 at 11:06 AM logoSangamo Therapeutics Announces Presentation At The 2017 Cantor Fitzgerald Global Healthcare Conference - September 23 at 6:20 AM logoWilliam R. Ringo Sells 31,000 Shares of Sangamo Therapeutics, Inc. (SGMO) Stock - September 22 at 7:52 PM logoSangamo Therapeutics, Inc. (SGMO) Receives "Buy" Rating from Jefferies Group LLC - September 14 at 7:16 PM logoSangamo Therapeutics, Inc. (SGMO) Earns Outperform Rating from Wells Fargo & Company - September 5 at 3:34 PM logoToday's Research Reports on Stocks to Watch: Sangamo Therapuetics and Nutanix - September 5 at 8:22 AM logoSangamo Therapeutics, Inc. (SGMO) Receives Consensus Recommendation of "Hold" from Brokerages - September 2 at 12:36 PM logoSangamo Presents T Cell Engineering Capabilities at Immuno-Oncology Summit - September 1 at 8:37 AM logoSangamo Therapeutics Announces Presentations At Upcoming Investor Conferences - August 31 at 9:59 AM logoSangamo Therapeutics Initiates Dosing in Hemophilia A Study - Nasdaq - August 30 at 9:07 AM logoWhy Abeona Therapeutics Inc. (and Maybe Sangamo Therapeutics, Inc.) Jumped Higher Today - August 29 at 6:52 PM logoSangamo Biosciences (SGMO), Pfizer (PFE) Announce First Patient Receives Treatment In Phase 1/2 Clinical Trial ... - - August 26 at 2:12 AM logoBreakfast Technical Briefing on Biotech Stocks -- Kite Pharma, Novavax, Sangamo Therapeutics, and Spectrum Pharma - August 21 at 8:06 AM logoSangamo Therapeutics: The Breakthrough In Gene Therapy - Seeking Alpha - August 17 at 9:37 PM logoSangamo Therapeutics (SGMO) Presents At Wedbush PacGrow Healthcare Conference - Slideshow - August 17 at 7:30 AM logoSangamo Therapeutics, Inc. – Value Analysis (NASDAQ:SGMO) : August 17, 2017 - August 17 at 7:30 AM logo Brokerages Expect Sangamo Therapeutics, Inc. (SGMO) Will Announce Earnings of -$0.23 Per Share - August 16 at 10:28 PM logoEquities Analysts Set Expectations for Sangamo Therapeutics, Inc.'s Q3 2017 Earnings (SGMO) - August 16 at 6:30 AM logoSangamo Therapeutics, Inc. (SGMO) VP Curt A. Herberts III Sells 11,474 Shares - August 15 at 8:00 PM logoSangamo Therapeutics Announces Presentation At The 2017 Wedbush PacGrow Healthcare Conference - August 11 at 8:28 AM logoSangamo Therapeutics, Inc. (SGMO) Announces Quarterly Earnings Results, Beats Estimates By $0.06 EPS - August 10 at 11:29 PM logoSangamo Therapeutics, Inc. (SGMO) PT Set at $8.00 by Piper Jaffray Companies - August 10 at 9:08 AM logoSangamo Therapeutics' (SGMO) CEO Sandy Macrae on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha - August 10 at 7:49 AM logoInvestor Network: Sangamo Therapeutics, Inc. to Host Earnings Call - August 10 at 7:49 AM logoSangamo Therapeutics Reports Second Quarter 2017 Financial Results - August 10 at 7:49 AM logoSangamo reports 2Q loss - August 10 at 7:49 AM logoEdited Transcript of SGMO earnings conference call or presentation 9-Aug-17 9:00pm GMT - August 10 at 7:49 AM logoSangamo Therapeutics, Inc. (NASDAQ:SGMO) Given Average Rating of "Hold" by Analysts - August 8 at 12:44 PM logoSangamo Therapeutics Announces Second Quarter 2017 Conference Call And Webcast - PR Newswire (press release) - August 4 at 8:08 AM logoSangamo Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : SGMO-US : August 3, 2017 - August 4 at 8:08 AM logoSangamo Therapeutics Announces Second Quarter 2017 Conference Call And Webcast - August 2 at 4:22 PM logo$6.79 Million in Sales Expected for Sangamo Therapeutics, Inc. (SGMO) This Quarter - July 31 at 9:23 AM logo-$0.24 EPS Expected for Sangamo Therapeutics, Inc. (SGMO) This Quarter - July 29 at 4:20 PM logoSangamo Therapeutics, Inc. (NASDAQ:SGMO) to Release Quarterly Earnings on Tuesday - July 27 at 8:14 PM



Sangamo Therapeutics (SGMO) Chart for Thursday, October, 19, 2017

This page was last updated on 10/19/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.